DNA icon

Autosomal Dominant Nocturnal Frontal Lobe Epilepsy via the CHRNB2 Gene

Summary and Pricing

Test Method

Sequencing and CNV Detection via NextGen Sequencing using PG-Select Capture Probes
Test Code Test Copy GenesTest CPT Code Gene CPT Codes Copy CPT Codes Base Price
CHRNB2 81405 81405,81479 $990
Test Code Test Copy Genes Test CPT Code Gene CPT Codes Copy CPT Code Base Price
8627CHRNB281405 81405,81479 $990 Order Options and Pricing

Pricing Comments

Testing run on PG-select capture probes includes CNV analysis for the gene(s) on the panel but does not permit the optional add on of exome-wide CNV analysis. Any of the NGS platforms allow reflex to other clinically relevant genes, up to whole exome or whole genome sequencing depending upon the base platform selected for the initial test.

An additional 25% charge will be applied to STAT orders. STAT orders are prioritized throughout the testing process.

This test is also offered via a custom panel (click here) on our exome or genome backbone which permits the optional add on of exome-wide CNV or genome-wide SV analysis.

Turnaround Time

3 weeks on average for standard orders or 2 weeks on average for STAT orders.

Please note: Once the testing process begins, an Estimated Report Date (ERD) range will be displayed in the portal. This is the most accurate prediction of when your report will be complete and may differ from the average TAT published on our website. About 85% of our tests will be reported within or before the ERD range. We will notify you of significant delays or holds which will impact the ERD. Learn more about turnaround times here.

Targeted Testing

For ordering sequencing of targeted known variants, go to our Targeted Variants page.


Genetic Counselors


  • Eric Bend, PhD

Clinical Features and Genetics

Clinical Features

Autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE, OMIM:600513) is a partial seizure disorder characterized by seizures that occur during non-REM sleep. Seizures in ADNFLE patients can present as repetitive limb movements, dystonic posturing, sleep walking, or sudden elevation of the body or head (Kurahashi and Hirose, GeneReviews, 2012). Seizures are brief, lasting from 5 seconds to 5 minutes, and often patients maintain consciousness throughout the attack. Frontal origin of ADNFLE seizures is revealed by ictal EEG recordings; interictal EEGs are normal. ADNFLE associated seizures are often managed with low doses of antieplieptic drugs (AEDs). ADNFLE is not generally associated with cognitive deficits or psychiatric problems, however, recent evidence suggests that a subset of ADNFLE-causing mutations may have wider neurological phenotypes (Steinlein et al. Seizure 21(2):118-123, 2012). ADNFLE can be difficult to clinically distinguish from other non-epileptic paroxysmal sleep disorders, therefore a video-polysomnography recording brain/eye/muscle activity during sleep is considered essential for diagnosis.


ADNFLE is inherited in an autosomal dominant manner. ADNFLE is a genetically heterogeneous disorder. Mutations in the CHRNB2 gene have been reported in ~5% of individuals with a family history of ADNFLE (Ottman et al. Epilepsia 51(4):655-670, 2010). The penetrance of CHRNB2 mutations is incomplete (~70%), thus ADNFLE presentation can be variable in families (Kurahashi and Hirose, 2012).

CHRNB2 encodes a neuronally expressed beta-subunit of the nicotinic acetylcholine receptor (nAChR). The nAChRs belong to a super-family of ligand-gated ion channels. All of the reported ADNFLE-associated CHRNB2 variants are missense mutations and most are located within the transmembrane domain of the receptor. Highly conserved residues within the transmembrane domain dictate the ligand-specificity and activity of the receptor. Reported mutations in CHRNB2 are gain of function mutations, resulting in an increased sensitivity of neuronal nAChRs to the agonist acetylcholine (Phillips et al. Am J Hum Genet. 68(1):225-231, 2001). It is hypothesized that increased nAchR activity underlies the epilepsy phenotype associated with CHRNB2 mutations.

Clinical Sensitivity - Sequencing with CNV PG-Select

Mutations in CHRNB2 account for ~5% of familial ADNFLE cases (Ottman et al. Epilepsia 51(4):655-670, 2010).

Testing Strategy

This test provides full coverage of all coding exons of the CHRNB2 gene, plus ~10 bases of flanking noncoding DNA. We define full coverage as >20X NGS reads or Sanger sequencing.

Indications for Test

Candidates for CHRNB2 sequencing include patients who display symptoms of ADNFLE and who have a family history of nocturnal seizures consistent with an autosomal dominant form of inheritance.


Official Gene Symbol OMIM ID
CHRNB2 118507
Inheritance Abbreviation
Autosomal Dominant AD
Autosomal Recessive AR
X-Linked XL
Mitochondrial MT


Name Inheritance OMIM ID
Epilepsy, Nocturnal Frontal Lobe, Type 3 605375

Related Test

Autosomal Dominant Nocturnal Frontal Lobe Epilepsy via the CHRNA4 Gene


  • Kurahashi H, Hirose S. 2012. Autosomal Dominant Nocturnal Frontal Lobe Epilepsy. In: Pagon RA, Adam MP, Ardinger HH, Bird TD, Dolan CR, Fong C-T, Smith RJ, and Stephens K, editors. GeneReviews(®), Seattle (WA): University of Washington, Seattle. PubMed ID: 20301348
  • Ottman R. et al. 2010. Epilepsia 51:655-70. PubMed ID: 20100225
  • Phillips HA, Favre I, Kirkpatrick M, Zuberi SM, Goudie D, Heron SE, Scheffer IE, Sutherland GR, Berkovic SF, Bertrand D. 2001. CHRNB2 Is the Second Acetylcholine Receptor Subunit Associated with Autosomal Dominant Nocturnal Frontal Lobe Epilepsy. The American Journal of Human Genetics 68: 225–231. PubMed ID: 11104662
  • Steinlein, O.K. et al. (2012). "Mutations in familial nocturnal frontal lobe epilepsy might be associated with distinct neurological phenotypes." Seizure 21(2):118:123. PubMed ID: 22036597


Ordering Options

We offer several options when ordering sequencing tests. For more information on these options, see our Ordering Instructions page. To view available options, click on the Order Options button within the test description.

myPrevent - Online Ordering

  • The test can be added to your online orders in the Summary and Pricing section.
  • Once the test has been added log in to myPrevent to fill out an online requisition form.
  • PGnome sequencing panels can be ordered via the myPrevent portal only at this time.

Requisition Form

  • A completed requisition form must accompany all specimens.
  • Billing information along with specimen and shipping instructions are within the requisition form.
  • All testing must be ordered by a qualified healthcare provider.

For Requisition Forms, visit our Forms page

If ordering a Duo or Trio test, the proband and all comparator samples are required to initiate testing. If we do not receive all required samples for the test ordered within 21 days, we will convert the order to the most effective testing strategy with the samples available. Prior authorization and/or billing in place may be impacted by a change in test code.

Specimen Types

Specimen Requirements and Shipping Details

loading Loading... ×


An error has occurred while calculating the price. Please try again or contact us for assistance.

View Ordering Instructions

1) Select Test Method (Platform)

1) Select Test Type

2) Select Additional Test Options

No Additional Test Options are available for this test.

Note: acceptable specimen types are whole blood and DNA from whole blood only.
Total Price: loading
Patient Prompt Pay Price: loading
A patient prompt pay discount is available if payment is made by the patient and received prior to the time of reporting.
Show Patient Prompt Pay Price
Copy Text to Clipboard